BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas

NCT ID: NCT07027423

Last Updated: 2025-12-01

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-03-30
• Study Completion Date: 2027-01-29

Brief Summary

A Phase 1b, non-randomized, single-institution trial designed to assess the safety, tolerability and the highest dose with acceptable toxicity (RP2D) of BOLD-100 in combination with doxorubicin in patients diagnosed with advanced soft tissue sarcomas. The trial is divided into two phases: an initial dose-escalation phase for BOLD-100, followed by a dose-expansion phase based on the recommended dose for Phase 2. In the dose-escalation phase, we plan to enroll 12-15 patients, with an additional 17 patients in the dose-expansion phase.

Participants will receive BOLD-100 intravenously on Days 1 and 8 of a 21-day cycle, in combination with doxorubicin (75 mg/m², intravenous) administered on Day 1 of each 21-day cycle for up to six cycles. Participants will continue to receive BOLD-100 for as long as the cancer is not getting worse, The maximum cycles of doxorubicin are 6 cycles.

Participants will undergo a screening assessment prior to the start treatment to determine eligibility for enrollment. Treatment will commence on Day 1 and will continue until the protocol-defined criteria for treatment withdrawal are met. Disease response will be assessed using CT or MRI scans, starting at 12 weeks after the initiation of treatment and continuing every 12 weeks until withdrawal.

Upon treatment discontinuation or study withdrawal, a post-treatment assessment will be conducted at end of treatment and at 30 days of the last BOLD-100 dose, with follow-up visits scheduled every 3 months thereafter.

Conditions

Sarcoma, Soft-tissue; Sarcoma; Sarcoma,Soft Tissue; Sarcomas

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BOLD-100 and Doxorubicin Dose Level -1

Escalation phase DL-1 - BOLD-100 230mg/m\^2 + Doxorubicin

Group Type: EXPERIMENTAL

BOLD-100

Intervention Type: DRUG

BOLD-100 in combination with Doxorubicin (Escalation)

Doxorubicin 75 mg/m^2

Intervention Type: DRUG

BOLD-100 in combination with Doxorubicin (Escalation)

BOLD-100 and Doxorubicin Dose Level 1

Escalation phase DL1 - BOLD-100 420mg/m\^2 + Doxorubicin

Group Type: EXPERIMENTAL

BOLD-100

Intervention Type: DRUG

BOLD-100 in combination with Doxorubicin (Escalation)

Doxorubicin 75 mg/m^2

Intervention Type: DRUG

BOLD-100 in combination with Doxorubicin (Escalation)

BOLD-100 and Doxorubicin Dose Level 2

Escalation phase DL2 - BOLD-100 500mg/m\^2 + Doxorubicin

Group Type: EXPERIMENTAL

BOLD-100

Intervention Type: DRUG

BOLD-100 in combination with Doxorubicin (Escalation)

Doxorubicin 75 mg/m^2

Intervention Type: DRUG

BOLD-100 in combination with Doxorubicin (Escalation)

BOLD-100 and Doxorubicin Dose Level 3

Escalation phase DL3 - BOLD-100 625mg/m\^2 + Doxorubicin

Group Type: EXPERIMENTAL

BOLD-100

Intervention Type: DRUG

BOLD-100 in combination with Doxorubicin (Escalation)

Doxorubicin 75 mg/m^2

Intervention Type: DRUG

BOLD-100 in combination with Doxorubicin (Escalation)

BOLD-100 and Doxorubicin

Exapsnion: BOLD-100 (RP2D) and Doxorubicin

Group Type: EXPERIMENTAL

BOLD-100

Intervention Type: DRUG

BOLD-100 in combination with Doxorubicin (Expansion)

Doxorubicin 75 mg/m^2

Intervention Type: DRUG

BOLD-100 in combination with Doxorubicin (Expansion)

Interventions

BOLD-100

BOLD-100 in combination with Doxorubicin (Escalation)

Intervention Type: DRUG

Doxorubicin 75 mg/m^2

BOLD-100 in combination with Doxorubicin (Escalation)

Intervention Type: DRUG

BOLD-100

BOLD-100 in combination with Doxorubicin (Expansion)

Intervention Type: DRUG

Doxorubicin 75 mg/m^2

BOLD-100 in combination with Doxorubicin (Expansion)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Written informed consent in accordance with federal, local, and institutional guidelines.

2. Age > 18 years.

3. Patients must have histologically confirmed locally advanced/unresectable or metastatic soft tissue sarcoma of limited subtype LMS, DDLPS and UPS (including Myxofibrosarcoma-MFS).

4. Patients be systemic treatment naïve, with incurable, advanced or metastatic disease.

5. Patient must have measurable disease as defined by RECIST 1.1.

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

7. Adequate hematopoietic function:

1. total white blood cell (WBC) count ≥2000/mm3.

2. absolute neutrophil count (ANC) ≥1500/mm3.

3. platelet count ≥100,000/mm3.

8. Adequate hepatic function:

1. Bilirubin <2 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of < 3 times ULN).

2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 X ULN. In the case of known (radiological and/or biopsy documented) liver metastasis, ALT/AST <5.0 X ULN is acceptable.

9. Adequate renal function defined as <1.5x upper limits of normal

10. Cardiac function: A normal left ventricular ejection fraction (LVEF) of > 50% as evidenced by an echocardiogram or nuclear medicine study performed within 28 days of the proposed study commencement.

11. Female patients of childbearing potential must agree to use two methods of contraception (including one highly effective and one effective method of contraception) and have a negative serum pregnancy test at 72 hours prior to receiving the first dose of study medication. Male patients must use an effective barrier method of contraception if sexually active with a female of childbearing potential. For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose of study treatment.

Exclusion Criteria

1. Patient is pregnant or lactating.

2. Radiation (except planned or ongoing palliative radiation outside of the region of measurable disease), chemotherapy, immunotherapy, any other systemic anticancer therapy, or participation in an investigational anti-cancer study ≤3 weeks prior to initiation of therapy.

3. Major surgery within 4 weeks before initiation of therapy.

4. Prior systemic therapy.

5. Unstable cardiovascular function:

1. symptomatic ischemia, or.

2. uncontrolled clinically significant conduction abnormalities (e.g., ventricular tachycardia on anti-arrhythmic is excluded and 1st degree AV block or asymptomatic LAFB/RBBB will not be excluded) or.

3. congestive heart failure (CHF) of NYHA Class ≥3, or.

4. myocardial infarction (MI) within 3 months of initiation of therapy.

6. Active, ongoing or uncontrolled active infection within one week prior to first dose.

7. Malignancies other than disease under study within 2 years prior to Cycle 1, Day 1, except for those with a negligible risk of metastasis or death (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ). Prior chemotherapy is allowed apart from regimens that contained anthracycline based therapies.

8. Known to be HIV seropositive.

9. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV) RNA or hepatitis B virus (HBV) surface antigen (HBsAg).

10. Patients with active CNS malignancy. Asymptomatic small lesions are not considered active. Treated lesions may be considered inactive if they are stable for at least 3 months.

11. Serious psychiatric or medical conditions that could interfere with treatment.

12. Concurrent therapy with approved or investigational anticancer therapeutic agents.

13. Any condition that, in the opinion of the Investigator, would interfere with evaluation of the study regimen or interpretation of patient safety or study results.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Health Network, Toronto

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

UHN- Princess Margaret Cancer Center

Toronto, Ontario, Canada

Countries

Canada

Central Contacts

Albiruni Razak, MD

Role: CONTACT

Albiruni.razak@uhn.ca

416 586 5371

Other Identifiers

BOLDSARC-01

Identifier Type: -

Identifier Source: org_study_id